Abilify Lawsuit 2026: Compulsive Gambling Claims, the FDA Warning & How to File

Abilify, one of the best-selling antipsychotics in history, is at the center of lawsuits alleging it triggered compulsive gambling, binge eating, compulsive shopping, and hypersexuality in patients with no prior history of those behaviors. The FDA issued a formal warning on May 3, 2016 — years after regulators in Europe and Canada had already acted.

Key Facts

  • On May 3, 2016, the FDA warned that aripiprazole (Abilify) was associated with "compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex," and told doctors to monitor patients and consider stopping the drug if compulsivity emerged.
  • The European Medicines Agency required a gambling warning in the fall of 2012, and Canadian regulators added one in November 2015 — the U.S. label did not adequately warn of the risk until the 2016 FDA action.
  • Federal Abilify lawsuits were consolidated as MDL 3:16-md-02734 in the Northern District of Florida; the FDA's review of 2005–2013 reports found 54 cases of compulsive or impulsive behaviors, 30 of them compulsive gambling.
  • In 2015, about 7.7 million prescriptions for oral aripiprazole were dispensed to roughly 1.6 million U.S. patients; Abilify recorded more than $5 billion in U.S. sales in 2014 alone.

What Abilify Is — and Why It Behaves Differently

Abilify is the brand name for aripiprazole, an antipsychotic approved by the FDA in 2002 for schizophrenia and bipolar I disorder, and later used as an add-on treatment for depression, for Tourette's syndrome, and for irritability associated with autism. It is a partial dopamine agonist. A dopamine agonist is a compound that stimulates dopamine receptors in the brain's reward and pleasure centers — and dopamine is the same neurotransmitter most closely linked to impulsive behavior and gambling.

That mechanism is the thread running through every lawsuit: the very action that calms psychosis may, in susceptible patients, unlock compulsions they never had. Plaintiffs repeatedly describe the same bewildering arc — a person with no gambling history who, months into treatment, is draining savings, maxing credit, and unable to stop.

The Warning That Came Late

The timeline is the heart of the liability argument. In the fall of 2012, European regulators required the label to reflect the possible connection with compulsive gambling. In November 2015, Canadian regulators concluded there was a link between aripiprazole and a possible risk of pathological gambling or hypersexuality, and added an explicit warning. Yet the U.S. label contained no adequate warning until the FDA's May 3, 2016 safety communication — fourteen years after the drug reached the American market.

In January 2016, the U.S. label had quietly added pathological gambling to a postmarketing section; the patient medication guide, the document most likely to be seen by patients and physicians, said nothing. The May 2016 FDA warning finally recommended that doctors make patients and caregivers aware of the risk, monitor closely, and consider reducing or stopping Abilify if uncontrollable urges appeared.

What the Lawsuits Allege

The core allegation is failure to warn: that Bristol-Myers Squibb and Otsuka knew of the compulsive-behavior signal years before the U.S. label reflected it, and continued marketing the drug without alerting American patients. Pathological gambling — which is gambling so severe it meets the clinical definition of a disorder — is the signature injury, but complaints also cover binge eating with major weight gain, compulsive shopping, and hypersexuality.

The FDA's adverse-event review found that in most of the 54 reported cases, the patient had no prior history of the compulsive behaviors, and that the urges typically stopped within days to weeks of discontinuing Abilify. That pattern — no history before, resolution after stopping — is what makes these cases medically distinctive. If you are taking the drug now, do not stop it on your own; withdrawal from an antipsychotic can be dangerous, and any change must go through your prescriber.

The MDL and the Money Already Paid

Federal cases were consolidated into multidistrict litigation before a Florida court (MDL No. 3:16-md-02734). MDL stands for multidistrict litigation, which is the federal procedure for coordinating similar lawsuits for pretrial proceedings. Parallel to the injury cases, the government extracted its own price: in December 2016, Bristol-Myers Squibb paid $19.5 million to 43 states and the District of Columbia to settle claims of deceptive off-label marketing of Abilify, and years earlier the company had paid more than $515 million to resolve federal illegal-marketing and pricing allegations.

Compensation varies widely by case, and most settlements are confidential. What is publicly documented is the scale of exposure: a drug with billions in sales, more than a decade of warnings abroad before the U.S. label caught up, and a regulator-confirmed side effect that destroyed finances and families.

Who May Qualify for a Claim

The typical profile in these lawsuits is a patient prescribed Abilify who developed new, uncharacteristic compulsive behaviors — most commonly gambling — with documented financial losses, who had no meaningful history of those behaviors before treatment, and whose compulsions eased after the drug was reduced or stopped. Medical records showing the prescription timeline, bank and credit records showing the losses, and testimony from family members who watched the change unfold are the three evidentiary pillars.

Drug-injury cases follow a similar anatomy across products. Our guides to the Xarelto bleeding-risk litigation and the Pradaxa settlement show the same pattern: a warning delayed, thousands injured, then a reckoning measured in documented settlements.

How to File — and What It Costs You

The practical path runs through a product-liability attorney who handles pharmaceutical cases, and these firms almost universally work on contingency: you pay nothing upfront, and the fee comes from any recovery. Bring your prescription history, a list of every prescriber, the dates the compulsive behavior began, and every financial record that shows the damage. Do not discard bank statements, casino or betting records, or credit-card bills — in gambling cases, the paper trail of losses is the damages case.

FAERS — the FDA Adverse Event Reporting System, which is the agency's database of postmarket safety reports — is where your doctor's report goes, and where the 54 cases that triggered the 2016 warning were counted. Reporting your own experience there costs nothing and contributes to the public record.

For plain-English explainers on lawsuits and money topics, watch Problem Solved on YouTube.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Patients prescribed Abilify who developed new, uncharacteristic compulsive behaviors, most commonly gambling, with documented financial losses. How: the typical profile is a patient with no meaningful history of those behaviors before treatment, whose compulsions eased after the drug was reduced or stopped, with prescription timelines and bank records to prove it.

Families who documented the financial damage. How: prescription history, a list of every prescriber, the dates the behavior began, and every financial record showing the damage are what a product-liability attorney asks for first.

People within the discovery-rule window. How: the FDA warning itself only arrived on May 3, 2016, so the clock may start when the patient learned, or should have learned, that the drug caused the injury, and a lawyer can calculate the exact window.

Who does not benefit:

People whose gambling or compulsive behavior predates Abilify and is unrelated to it. How: the typical claim profile requires new behavior with no meaningful prior history, so a long-standing pattern points away from the drug.

Anyone expecting a payout from the government settlements. How: the 19.5 million dollar multistate settlement in December 2016 and the earlier 515 million dollar federal settlement were government actions over marketing, not patient compensation funds.

Anyone planning to stop an antipsychotic on their own. How: withdrawal can be dangerous, and the FDA advised doctors to monitor patients and consider reducing or stopping the drug if urges emerge, so any change must go through the prescriber.

A parallel antipsychotic litigation is covered in our guide to the Risperdal lawsuit, where the older claims are largely closed but newer claims may still be viable.

Frequently Asked Questions

Can Abilify really cause compulsive gambling?

The FDA says the association is real: on May 3, 2016, it warned that aripiprazole was associated with compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex. Its review found 54 reported cases from 2005–2013, most with no prior history of such behaviors.

What was the Abilify lawsuit settlement?

The most clearly documented resolutions are government actions: a $19.5 million multistate settlement in December 2016 over deceptive marketing, and an earlier $515 million-plus federal settlement over illegal marketing and pricing. Individual injury settlements are mostly confidential.

Do I still take Abilify if I have a claim?

Never stop an antipsychotic on your own — withdrawal can be dangerous. The FDA advised doctors to monitor patients for compulsivity and consider reducing or stopping the drug if urges emerge; any change must go through your prescriber.

How long do I have to file an Abilify lawsuit?

Deadlines vary by state, and the discovery rule — which starts the clock when you learned, or should have learned, that the drug caused your injury — may apply, since the FDA warning itself only arrived in 2016. A lawyer can calculate your exact window.

Who qualifies for an Abilify compulsive gambling claim?

Patients prescribed Abilify who developed new compulsive gambling with documented financial losses, no meaningful history of that behavior before treatment, and urges that eased after the drug was reduced or stopped fit the typical claim profile.

Who does not qualify for an Abilify claim?

People whose compulsive behavior predates Abilify or is unrelated to it generally do not qualify, and neither do people with no prescription records or no documented financial losses, since the prescription timeline and the damage records are central to the claim.

Disclaimer: This article is general information, not legal or medical advice. It is not a substitute for professional medical guidance, and drug-injury claims have strict deadlines that vary by state; consult a licensed attorney and your doctor before acting.

Watch on YouTube

Problem Solved on YouTube